Subtopic Deep Dive
TGF-β Signaling in Liver Fibrogenesis
Research Guide
What is TGF-β Signaling in Liver Fibrogenesis?
TGF-β signaling in liver fibrogenesis refers to Smad-dependent and independent pathways in TGF-β that drive fibrogenic gene expression and extracellular matrix deposition in hepatic stellate cells (HSCs) and hepatocytes during liver fibrosis progression.
TGF-β activates HSCs, the primary fibrogenic cells, leading to collagen production and fibrosis (Dewidar et al., 2019, 728 citations). Smad signaling mediates canonical TGF-β effects, while non-Smad paths contribute in chronic injury (Xu et al., 2016, 700 citations). Studies identify regulators like miR-29 downregulation and miR-21 feedback loops (Roderburg et al., 2010, 782 citations; Zhang et al., 2013, 126 citations). Over 10 key papers span miRNA modulation and pathway inhibitors.
Why It Matters
TGF-β drives HSC activation central to liver fibrosis progressing to cirrhosis, with no approved antifibrotic drugs, making pathway inhibition a prime therapeutic target (Dewidar et al., 2019). Inhibitors like curcumin via PPARγ block TGF-β-induced ECM genes in HSCs (Zheng and Chen, 2004). Isorhamnetin suppresses Smad signaling and oxidative stress in fibrosis models (Yang et al., 2016). MiR-29 restoration reduces collagen in human and murine fibrosis (Roderburg et al., 2010). These mechanisms guide drug development for fibrosis regression.
Key Research Challenges
TGF-β Pathway Heterogeneity
Acute versus chronic liver injuries show differential Smad signaling regulation in HSCs (Yoshida and Matsuzaki, 2012). Canonical Smad paths dominate chronic fibrogenesis, while non-Smad paths vary. This complicates uniform inhibitor design (Xu et al., 2016).
TGF-β Independent Fibrosis
IL-13 induces fibrosis via TGF-β-independent mechanisms involving tissue inhibitors of metalloproteinases (Kaviratne et al., 2004). This challenges TGF-β-centric therapies. Overlapping paths require multi-target strategies (Dewidar et al., 2019).
MicroRNA Feedback Loops
MiR-21/PDCD4/AP-1 loop sustains HSC activation and fibrosis (Zhang et al., 2013). MiR-29 downregulation promotes ECM deposition (Roderburg et al., 2010). Targeting these loops faces off-target effects in vivo.
Essential Papers
Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis
Christoph Roderburg, Gerd-Willem Urban, Kira Bettermann et al. · 2010 · Hepatology · 782 citations
Liver fibrosis is orchestrated by a complex network of signaling pathways regulating the deposition of extracellular matrix proteins during fibrogenesis. MicroRNAs (miRNAs) represent a family of sm...
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Bedair Dewidar, Christoph Meyer, Steven Dooley et al. · 2019 · Cells · 728 citations
Liver fibrosis is an advanced liver disease condition, which could progress to cirrhosis and hepatocellular carcinoma. To date, there is no direct approved antifibrotic therapy, and current treatme...
TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis
Fengyun Xu, Changwei Liu, Dandan Zhou et al. · 2016 · Journal of Histochemistry & Cytochemistry · 700 citations
Transforming growth factor-beta1 (TGF-β1), a key member in the TGF-β superfamily, plays a critical role in the development of hepatic fibrosis. Its expression is consistently elevated in affected o...
Apoptosis: The nexus of liver injury and fibrosis
Ali Canbay, Scott L. Friedman, Gregory J. Gores · 2004 · Hepatology · 519 citations
Apoptosis associated with liver disease is increasingly viewed as a nexus through which many key pathways converge. Apoptotic responses incorporate soluble stimuli, inflammatory cells, resident par...
IL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF-β Independent
Mallika Kaviratne, Matthias Hesse, Mary Leusink et al. · 2004 · The Journal of Immunology · 366 citations
Abstract Fibrosis is a characteristic feature in the pathogenesis of a wide spectrum of diseases. Recently, it was suggested that IL-13-dependent fibrosis develops through a TGF-β1 and matrix metal...
Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis
Isabel Fabregat, Daniel Caballero‐Díaz · 2018 · Frontiers in Oncology · 340 citations
The Transforming Growth Factor-beta (TGF-β) family plays relevant roles in the regulation of different cellular processes that are essential for tissue and organ homeostasis. In the case of the liv...
Differential Regulation of TGF-β/Smad Signaling in Hepatic Stellate Cells between Acute and Chronic Liver Injuries
Katsunori Yoshida, Koichi Matsuzaki · 2012 · Frontiers in Physiology · 129 citations
Current evidence suggests that regulation of extracellular matrix (ECM) accumulation by fibrogenic transforming growth factor (TGF)-β and platelet-derived growth factor (PDGF) signals involves diff...
Reading Guide
Foundational Papers
Start with Roderburg et al. (2010, 782 citations) for miR-29 in fibrogenesis networks; Canbay et al. (2004, 519 citations) for apoptosis-fibrosis links; Kaviratne et al. (2004, 366 citations) for TGF-β-independent mechanisms.
Recent Advances
Dewidar et al. (2019, 728 citations) updates HSC activation; Fabregat and Caballero-Díaz (2018, 340 citations) covers cell plasticity; Yang et al. (2016, 109 citations) tests isorhamnetin inhibition.
Core Methods
Smad signaling assays, miRNA profiling (Roderburg et al., 2010), HSC activation models (Dewidar et al., 2019), inhibitor screens like PPARγ activation (Zheng and Chen, 2004), immunohistochemistry for pathway activation (Xu et al., 2016).
How PapersFlow Helps You Research TGF-β Signaling in Liver Fibrogenesis
Discover & Search
Research Agent uses searchPapers and citationGraph to map TGF-β papers from Dewidar et al. (2019, 728 citations), revealing clusters around HSC activation and Smad paths. exaSearch uncovers miR-29 fibrosis regulators like Roderburg et al. (2010). findSimilarPapers expands from Xu et al. (2016) to 50+ related Smad studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract TGF-β/Smad mechanisms from Dewidar et al. (2019), then verifyResponse with CoVe checks inhibitor efficacy claims against Yang et al. (2016). runPythonAnalysis performs statistical verification of miRNA expression correlations from Roderburg et al. (2010) data using pandas, with GRADE grading for evidence strength in fibrogenesis pathways.
Synthesize & Write
Synthesis Agent detects gaps in TGF-β-independent fibrosis paths versus Smad dominance, flags contradictions between IL-13 mechanisms (Kaviratne et al., 2004) and canonical models. Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing Dewidar et al. (2019), with latexCompile for publication-ready output and exportMermaid for signaling pathway diagrams.
Use Cases
"Extract and plot miR-29 expression data from Roderburg 2010 to correlate with fibrosis stage."
Research Agent → searchPapers('miR-29 liver fibrosis') → Analysis Agent → readPaperContent(Roderburg et al., 2010) → runPythonAnalysis(pandas plot of expression vs. fibrosis) → matplotlib figure of downregulation trends.
"Write LaTeX review section on TGF-β inhibitors in HSCs citing Dewidar 2019 and Yang 2016."
Synthesis Agent → gap detection(TGF-β inhibitors) → Writing Agent → latexEditText('HSC activation review') → latexSyncCitations(Dewidar 2019, Yang 2016) → latexCompile → PDF with formatted antifibrotic discussion.
"Find GitHub code for TGF-β signaling models from recent liver fibrosis papers."
Research Agent → searchPapers('TGF-β liver fibrogenesis simulation') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for Smad pathway simulations linked to Xu et al. (2016).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ TGF-β papers: searchPapers → citationGraph(Dewidar et al., 2019 hub) → structured report on Smad vs. non-Smad paths. DeepScan applies 7-step analysis with CoVe checkpoints to verify miR-21 loop claims (Zhang et al., 2013). Theorizer generates hypotheses on miR-29/PPARγ synergies for fibrosis resolution from Roderburg et al. (2010) and Zheng and Chen (2004).
Frequently Asked Questions
What defines TGF-β signaling in liver fibrogenesis?
TGF-β signaling drives HSC activation via Smad-dependent transcription of fibrogenic genes like collagen, with elevated TGF-β1 correlating to ECM accumulation (Xu et al., 2016; Dewidar et al., 2019).
What are key methods studying TGF-β paths?
Methods include miRNA profiling for regulators like miR-29 (Roderburg et al., 2010), HSC culture assays for inhibitor testing (Zheng and Chen, 2004; Yang et al., 2016), and immunohistochemistry for Smad activation (Xu et al., 2016).
What are landmark papers?
Roderburg et al. (2010, 782 citations) links miR-29 to fibrosis; Dewidar et al. (2019, 728 citations) reviews HSC TGF-β activation; Canbay et al. (2004, 519 citations) ties apoptosis to fibrogenesis.
What open problems exist?
Developing TGF-β inhibitors without disrupting homeostasis; resolving TGF-β-independent paths like IL-13 fibrosis (Kaviratne et al., 2004); targeting chronic-specific Smad regulation (Yoshida and Matsuzaki, 2012).
Research Liver physiology and pathology with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching TGF-β Signaling in Liver Fibrogenesis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Liver physiology and pathology Research Guide